Chinese Medical Association

Corxel Pharmaceuticals and LENZ Therapeutics announced positive phase 3 JX07001 trial results for LNZ100, showing significant improvements in near vision and maintenance of distance vision in Chinese presbyopic patients. LNZ100 demonstrated rapid onset, long duration, and was well-tolerated, with no serious adverse events. The study highlights LNZ100's potential as a global therapy for presbyopia.

Corxel Pharmaceuticals and LENZ Therapeutics announced positive phase 3 JX07001 trial results for LNZ100, showing significant improvements in near vision with no loss of distance vision in Chinese presbyopic patients. LNZ100 demonstrated rapid onset, long duration, and was well-tolerated, with no serious adverse events. The study highlights LNZ100's potential as a global therapy for presbyopia.

CORXEL and LENZ Therapeutics announce positive Phase 3 data for LNZ100 in China, showing 74% of participants achieved three-lines or greater improvement at 3 hours post-treatment for presbyopia, with rapid onset (69% at 30 minutes) and sustained efficacy (30% at 10 hours). LNZ100 was well-tolerated, and the FDA has accepted the New Drug Application for the US market.

LNZ100, an aceclidine-based eye drop, showed significant improvement in near vision for presbyopia patients in a Phase 3 trial in China, with 74% achieving three-lines or greater improvement at 3 hours post-treatment. The treatment demonstrated rapid onset and long duration, with 69% improving at 30 minutes and 30% at 10 hours. LNZ100 was well-tolerated, with no serious adverse events reported.

Pembrolizumab plus CCRT showed higher PFS rates (77.6%) vs placebo plus CCRT (59.8%) in East Asia subgroup of high-risk, locally advanced cervical cancer patients, with manageable safety profiles.

UltraDx Bio's UD-X™ Single-Molecule Analyzer received China's first clinical registration approval, revolutionizing early screening for Alzheimer's Disease. The analyzer, listed on the National Medical Products Administration website, detects trace protein biomarkers at the fg/ml scale, addressing precision detection needs in clinical diagnostics.